GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoMed Pharmaceuticals Inc (NAS:OMED) » Definitions » PS Ratio

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) PS Ratio : 0.77 (As of Apr. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is OncoMed Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, OncoMed Pharmaceuticals's share price is $0.89. OncoMed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $1.16. Hence, OncoMed Pharmaceuticals's PS Ratio for today is 0.77.

The historical rank and industry rank for OncoMed Pharmaceuticals's PS Ratio or its related term are showing as below:

OMED's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.98
* Ranked among companies with meaningful PS Ratio only.

OncoMed Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2018 was $0.26. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $1.16.

Back to Basics: PS Ratio


OncoMed Pharmaceuticals PS Ratio Historical Data

The historical data trend for OncoMed Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoMed Pharmaceuticals PS Ratio Chart

OncoMed Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
PS Ratio
Get a 7-Day Free Trial Premium Member Only 16.35 26.12 9.99 4.05 0.65

OncoMed Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 3.03 2.17 1.48 0.65

Competitive Comparison of OncoMed Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, OncoMed Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoMed Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoMed Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where OncoMed Pharmaceuticals's PS Ratio falls into.



OncoMed Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

OncoMed Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.89/1.155
=0.77

OncoMed Pharmaceuticals's Share Price of today is $0.89.
OncoMed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.16.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


OncoMed Pharmaceuticals  (NAS:OMED) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


OncoMed Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of OncoMed Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 Chesapeake Drive, Redwood City, CA, USA, 94063
OncoMed Pharmaceuticals Inc is a clinical-stage biotechnology company. The aim of the company is to address cancer initiation, growth, metastases, and recurrence by developing alternative therapies to fight cancer. Its core therapy uses monoclonal antibodies targeting cancer stem cells. The company has strategic alliances with Celgene, Bayer Pharma, and GlaxoSmithKline.
Executives
Perry A Karsen director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Jack W Lasersohn director 18 BANK STREET, SUMMIT NJ 07901
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Denise Scots-knight director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Sunil Patel officer: See Remarks 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Paul J Hastings officer: Chairman & CEO 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Laurence Lasky director C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jakob Dupont officer: SVP & Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Terry P Gould director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Usvp Entrepreneur Partners Viii A L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Entrepreneur Partners Viii B L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Viii Affiliates Fund L P 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025